Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | C1S | P09871 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838580 | 0.86 | PARP1 (0.63) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| SCHEMBL30153175 | 0.86 | PARP1 (0.68) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| SCHEMBL241785 | 0.86 | PARP1 (0.68) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| SCHEMBL40538 | 0.84 | ATM (0.71) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL27869733 | 0.84 | PARP1 (0.65) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| SCHEMBL3838117 | 0.82 | PARP1 (0.59) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| SCHEMBL11290390 | 0.79 | MAPT (0.58) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| SCHEMBL5687920 | 0.78 | LMNA (0.57) | L3MBTL1TDP1ALDH1A1HTTHPGD | |
| SCHEMBL9353635 | 0.78 | FLT1 (0.55) | PARP1L3MBTL1TDP1ATMALDH1A1 | |
| SCHEMBL19530988 | 0.78 | LMNA (0.63) | PARP1L3MBTL1TDP1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| CN-1842516-A | Amide compounds and method for controlling plant diseases using the same | SUMITOMO CHEMICAL CO (JP) | 2006-10-04 | — | — | CN | disclosed |
| US-20060122064-A1 | Amides and method for plant diseases control with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1640360-A1 | AMIDES AND METHOD FOR PLANT DISEASE CONTROL WITH THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| CN-1152864-C | Phenylphenanthridines with PDE-IV inhibiting activity | ��̹��ҽҩ��˾ | 2004-06-09 | — | — | CN | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
| CN-1336919-A | Phenylphenanthridines with PDE-IV inhibiting activity | BYK GULDEN LOMBERG CHEM FAB (DE) | 2002-02-20 | — | — | CN | disclosed |
| EP-1147089-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | disclosed |
| CN-1301305-A | Serine protease variants with amino acid substitutions | PROCTER & GAMBLE (US) | 2001-06-27 | — | — | CN | disclosed |
| WO-2000042020-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122064-A1 | Amides and method for plant diseases control with the same | ARG1, ARGLU1, ARG2 | PARP1 4554/4885L3MBTL1 4/4885TDP1 4142/4885 |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | PARP1 2792/4885L3MBTL1 4348/4885TDP1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.